Why Invest in Electromed
- Large, expanding bronchiectasis market supported by industry tailwinds
- Clinically proven therapy
- Well established reimbursement code with broad payer coverage
- Consistent double-digit organic revenue growth
- History of high gross margins, robust operating cash flow and increased operating leverage
- Attractive valuation at 1.8x EV/Revenue
Corporate Strategy
- Continued sales force expansion along with complementary infrastructure investments
- Direct-to-consumer and physician marketing to increase brand awareness and revenue
- Best-in-class customer care and support
- Develop and promulgate the body of bronchiectasis clinical evidence to increase physician adoption of the SmartVest® System for patients
- Promote the best-in-class SmartVest Clearway® device
Vision: Improve quality of life for a greater number of patients with compromised pulmonary function and reduce overall healthcare utilization through therapy with SmartVest® Airway Clearance System.